MBBS, FACEM, FCICM
Nima grew up in Canada, completing her undergraduate training in British Columbia, before moving to Australia to complete her medical training. After fulfilling her Australian College of Emergency Medicine requirements in 2011, Nima completed her College of Intensive Care Medicine Fellowship requirements in early 2015. She is trained in critical care echocardiography, ECMO, paediatric care, and has spent the last year of her training as a Critical Care Fellow at The Austin ICU, the state spinal and liver transplant centre.
Head of Education
Nima is the lead for the ICU education portfolio
Latest news:
-
Thursday, August 26, 2021 - 01:57
JAMA BaSICS rate: Slower vs faster fluid challenge in critically ill patients not significantly reduce 90-day mortality. In addition there was a lower use of vasopressors on day 3 in the slower infusion rate group. Adds to SPLIT and SMART trials.
Monday, August 23, 2021 - 13:54NEJM Convalescent plasma RCT for high-risk patients present to ED within 7 days after the onset of symptoms = no difference disease progression
Monday, August 23, 2021 - 12:27NEJM VITT review 237 suspected from 24 million Oxford-Astra Zeneca doses, incidence at least 1:100,000 >50 years, 1:50,000 <50 years, occurs 5-30 days after first dose. Extensive thrombotic sites, cerebral venous thrombosis dominant. Low platelets, increased D-dimer, reduced fibrinogen associated worse outcomes. Overall case fatality rate 23%, highest in patients with both ICH and platelet count below 30,000. No therapeutic options proven effective, although IVIG, corticosteroids, plasma exchange, and non-heparin anticoagulation are used.
Sunday, August 22, 2021 - 19:03JC DOREMI RCT reports no difference in composite primary outcome with milrinone vs dobutamine for cardiogenic shock (49% M vs 54% D, RR, 0.90; 95% CI, 0.69 to 1.19; P=0.47). No difference in secondary outcomes. It was powered to detect a large effect.
Sunday, August 22, 2021 - 11:21REMAP-CAP, ACTIV-4a, and ATTACC harmonised multiplatform, randomized trial 2244 non-ICU patients with COVID- for every 1000 patients, therapeutic anticoagulation vs thromboprophylaxis expected to result in 40 additional patients surviving to hospital discharge without organ support, and 7 major bleeds.